Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal
jktugmandht2017-06-03T13:11:16-04:00by Frank Vinluan | April 24th, 2017 Xconomy New York — In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for products used in treating vascular conditions and cancer. Under the deal announced Sunday, [...]